Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits

Atherosclerosis. 1995 Apr 7;114(1):29-44. doi: 10.1016/0021-9150(94)05460-z.


We have characterized the extent and the phenotype of total and proliferating cell population of aortic plaques in aged rabbits receiving a long-term low-dose cholesterol hyperlipemic diet, which represents an experimental model of atherosclerosis. For nine months, rabbits received the hypercholesterolemic diet alone or in addition to a treatment with propionyl-L-carnitine (PLC), a derivative of carnitine, an intramitochondrial carrier of fatty acids present in most cell types. We observed that, in both PLC-treated and control hyperlipemic rabbits, the ratio between proliferating macrophage-derived and smooth muscle cells was 2:1. PLC in addition to the hypercholesterolemic diet induced a marked lowering of plasma triglycerides, very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) triglycerides, while plasma cholesterol was slightly and transiently reduced. Moreover, PLC-treated hyperlipemic rabbits exhibited a reduction of plaque thickness and extent, a slight but significant reduction of the percentage of macrophage-derived cells as compared to control hyperlipemic animals and a reduction of the number of both proliferating macrophage- and smooth muscle cell-derived foam cells. Finally, both proliferating and non-proliferating plaque cells expressed large amounts of macrophage colony-stimulating factor protein, in particular macrophage-derived foam cells. These results indicate that a modification of plasma lipemic pattern obtained by a long-term oral administration of PLC was associated with a decrease of plaque cell proliferation and severity of aortic atherosclerotic lesions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging
  • Animals
  • Arteriosclerosis / metabolism
  • Arteriosclerosis / pathology*
  • Arteriosclerosis / prevention & control*
  • Carnitine / administration & dosage
  • Carnitine / analogs & derivatives*
  • Carnitine / pharmacology
  • Cell Division / drug effects
  • Diet
  • Disease Models, Animal
  • Female
  • Foam Cells / pathology*
  • Hyperlipidemias / metabolism
  • Hyperlipidemias / pathology
  • Hyperlipidemias / prevention & control
  • Immunohistochemistry
  • Lipoproteins, VLDL / metabolism
  • Male
  • Muscle, Smooth, Vascular / pathology*
  • Rabbits


  • Lipoproteins, VLDL
  • propionylcarnitine
  • Carnitine